(-)-Epigallocatechin Gallate [989-51-5]

Katalog-Nummer HY-13653-100mg

Size : 100mg

Marke : MedChemExpress

Contact local distributor :


Telefonnummer : +1 850 650 7790

(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

(-)-Epigallocatechin Gallate Chemische Struktur

(-)-Epigallocatechin Gallate Chemische Struktur

CAS. Nr. : 989-51-5

This product is a controlled substance and not for sale in your territory.

Based on 31 publication(s) in Google Scholar

Other Forms of (-)-Epigallocatechin Gallate:

  • (-)-Epigallocatechin Gallate (Standard) In-stock
  • (-)-Epigallocatechin In-stock
  • (-)-Gallocatechin gallate In-stock
  • (+/-)-Epigallocatechin Gallate-13C3 Angebot einholen

    (-)-Epigallocatechin Gallate purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2017 Nov;14(5):6314-6320.  [Abstract]

    Effects of EGCG on the levels of SHP 1 and p p38α protein expres¬sion in NB4 cells.
    Beschreibung

    (-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4].

    IC50 & Target[1]

    EGFR

     

    HER2

     

    HER3

     

    In Vitro

    (-)-Epigallocatechin Gallate (EGCG, 10-60 μM) inhibits the growth of FB-2 and WRO cells in a dose-dependent manner[1].
    (-)-Epigallocatechin Gallate (10-60 μM, 0-24 h) reduces cyclin D1 and phosphorylation of AKT and ERK1/2, and increases p21 and p53 expression[1].
    (-)-Epigallocatechin Gallate (10-60 μM, 12 h) reduces cell motility and migration[1].
    (-)-Epigallocatechin Gallate (0-20 μM, 0-20 min approximately) inhibits GLUD1/2 and IDH1 activity in a concentration and time-dependent way (biochemical assays)[2].
    (-)-Epigallocatechin Gallate (0-35 μg/mL, 24-72 h) inhibits the proliferation of colorectal cancer cells (LoVo, SW480, HT-29, HCT-8 cells), increases cell apoptosis and blocks cells at the G0/G1 phase[3].
    (-)-Epigallocatechin Gallate (30 μM, 3-24 h) suppresses the expression of COX-2 and mPGES-1 mRNAs, prostaglandin E2 production in LPS-induced osteoblasts[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Proliferation Assay[1]

    Cell Line: FB-2 and WRO cells (serum-starved for 48h)
    Concentration: 10, 40, 60 μM.
    Incubation Time: 4 days
    Result: Inhibited basal cell proliferation (40% in FB-2 and 35% in WRO) at 10 μM, inhibited cell number (by 68% to 73%) at 40 and 60 μM).

    Western Blot Analysis[1]

    Cell Line: FB-2 cells
    Concentration: 10, 40, 60 μM.
    Incubation Time: 24 h
    Result: Reduced cyclin D1 level, phosphorylation of AKT and ERK1/2.
    Induced the expression of p21 and p53, and E-cadherin, N-cadherin, Vimentin and α5-integrin.

    Cell Migration Assay [1]

    Cell Line: FB-2 and WRO cells (serum-starved for 48h)
    Concentration: 10, 40, 60 μM.
    Incubation Time: 12 h
    Result: Reduced migration activity in FB-2 and WRO cells.

    RT-PCR[4]

    Cell Line: Mouse primary osteoblasts (1 ng/ml LPS-treated)
    Concentration: 30 μM
    Incubation Time: 3, 6, 12, 24 h
    Result: Suppressed the LPS-induced expression of COX-2 and mPGES-1 mRNAs, prostaglandin E2 production.
    In Vivo

    (-)-Epigallocatechin Gallate (Intragastrical administration, 5-20 mg/kg, once daily for 14 days, orthotopic transplant model) decreases tumors growth[3].
    (-)-Epigallocatechin Gallate (Injected into the mouse lower gingiva, a single dose of 0.5 mg/mouse, experimental periodontitis model) decreases inhibits the LPS-induced loss of bone mineral density (BMD)[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Orthotopic transplant BALB/c nude mice model[3]
    Dosage: 5, 10, and 20 mg/kg, once daily for 14 days.
    Administration: Intragastrical administration.
    Result: Inhibited tumors growth with no liver or lung metastases.
    Animal Model: Model of experimental periodontitis, LPS (25 μg/mouse)[4]
    Dosage: 0.5 mg/mouse, a single dose.
    Administration: Injected into the mouse lower gingiva
    Result: Inhibited the LPS-induced loss of bone mineral density (BMD) in mice.
    Klinische Studie
    Molekulargewicht

    458.37

    Formel

    C22H18O11

    CAS. Nr.

    989-51-5

    Appearance

    Solid

    Color

    Off-white to pink

    SMILES

    O=C(O[C@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1)C4=CC(O)=C(O)C(O)=C4

    Structure Classification
    • Flavonoids
    • Flavonones
    • Phenols
    • Polyphenols
    Initial Source
    • Plants
    • other families
    • Endogenous metabolite
    Versand

    Room temperature in continental US; may vary elsewhere.

    Speicherung
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Lösungsmittel & Löslichkeit
    In Vitro: 

    DMSO : ≥ 30 mg/mL (65.45 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : 20 mg/mL (43.63 mM; Need ultrasonic)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.1816 mL 10.9082 mL 21.8164 mL
    5 mM 0.4363 mL 2.1816 mL 4.3633 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molaritätsrechner

    • Verdünnungsrechner

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 9.09 mg/mL (19.83 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Reinheit & Dokumentation

    Purity: 99.87%

    Verweise
    • [1]. De Amicis F, et al. Epigallocatechin gallate inhibits growth and Epithelial-to-Mesenchymal Transition in human thyroid carcinoma cell lines. J Cell Physiol. 2013 Apr 1.  [Content Brief]

      [2]. Peeters TH, et al. Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate. Cancer Metab. 2019 May 20;7:4.  [Content Brief]

      [3]. Jin H, et al. Epigallocatechin gallate inhibits the proliferation of colorectal cancer cells by regulating Notch signaling. Onco Targets Ther. 2013;6:145-53.  [Content Brief]

      [4]. Tsukasa Tominari; Epigallocatechin gallate (EGCG) suppresses lipopolysaccharide-induced inflammatory bone resorption, and protects against alveolar bone loss in mice. FEBS Open Bio. 2015 Jun 12;5:522-7.  [Content Brief]

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 2.1816 mL 10.9082 mL 21.8164 mL 54.5411 mL
    5 mM 0.4363 mL 2.1816 mL 4.3633 mL 10.9082 mL
    10 mM 0.2182 mL 1.0908 mL 2.1816 mL 5.4541 mL
    15 mM 0.1454 mL 0.7272 mL 1.4544 mL 3.6361 mL
    20 mM 0.1091 mL 0.5454 mL 1.0908 mL 2.7271 mL
    25 mM 0.0873 mL 0.4363 mL 0.8727 mL 2.1816 mL
    30 mM 0.0727 mL 0.3636 mL 0.7272 mL 1.8180 mL
    40 mM 0.0545 mL 0.2727 mL 0.5454 mL 1.3635 mL
    DMSO 50 mM 0.0436 mL 0.2182 mL 0.4363 mL 1.0908 mL
    60 mM 0.0364 mL 0.1818 mL 0.3636 mL 0.9090 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    (-)-Epigallocatechin Gallate Related Classifications

    Help & FAQs

    Keywords:

    (-)-Epigallocatechin Gallate989-51-5EGCG Epigallocatechol GallateEndogenous MetaboliteApoptosisThyroid cancerFB-2 cellsLPS-induced bone resorptioncolorectal cancercell proliferation.Inhibitorinhibitorinhibit

    Sie könnten auch an folgenden Produkten interessiert sein:



    Katalog-Nummer
    Beschreibung
    Cond.
    Preis zzgl. MwSt.
    HY-10162-500mg
     500mg 
    HY-14590-50mg
     50mg